Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $50 price target on Deciphera after its in-line Q4 results, saying the company’s development of ripretinib is progressing nicely with ongoing phase 3 enrollment in INTRIGUE study and results for INVICTUS study expected later this year. The analyst remains positive on the shares given the company’s “catalyst-rich” second half of the year on tap.
https://thefly.com/landingPageNews.php?id=2879635
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.